Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer: A single-centre study of 163 patients. Issue 3 (March 2015)

• Record Type: Journal Article
• Authors: Miyata, Y.; Nomata, K.; Ohba, K.; Matsuo, T.; Hayashi, N.; Sakamoto, I.; Uetani, M.; Sakai, H.
• Is Part Of: European journal of surgical oncology. Volume 41:Issue 3(2015:Mar.)
• Page Start: 361
• Page End: 367
• Publication Date: 2015-03
• Subjects: Oncology -- Periodicals; Cancer -- Surgery -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- surgery -- Periodicals; Cancer -- Chirurgie -- Périodiques; Cancérologie -- Périodiques; Oncologie; Chirurgie (geneeskunde); Electronic journals; Electronic journals -- Sciences; Electronic journals -- Medicine; Electronic journals; 616.994059005
• DOI: 10.1016/j.ejso.2014.07.043
• Languages: English
• ISSNs: 0748-7983

Abstract

<abstract xml:lang="en" abstract-type="author" id="abs0010"> <title id="sectitle0010">Abstract</title> <sec> <title id="sectitle0015">Introduction</title> <p id="abspara0010">Patients with muscle-invasive bladder cancer (MIBC) often undergo various preoperative treatments to improve survival; however, their efficacy and safety remain unclear.</p> </sec> <sec> <title id="sectitle0020">Materials and methods</title> <p id="abspara0015">The anti-tumour effects and adverse events were evaluated in 163 MIBC patients who received systemic chemotherapy (SC, <italic>n</italic> = 34), intra-arterial chemotherapy (IAC, <italic>n</italic> = 50), or combined IAC and radiotherapy (IAC + R, <italic>n</italic> = 79).</p> </sec> <sec> <title id="sectitle0025">Results</title> <p id="abspara0020">Pathological complete responses were observed in 17.6%, 22.0%, and 43.0% of patients in the SC, IAC, and IAC + R groups, respectively, with respective 5-year overall survival rates of 42.0%, 46.7%, and 50.3%. Multivariate analysis showed that successful IAC + R protocol administration was a significant predictor for survival (hazard ratio = 0.16, <italic>p</italic> = 0.028). The incidence of severe adverse events was higher in the IAC + R group (36.7%) than in the SC (9.8%) and IAC groups (16.0%).</p> </sec> <sec> <title id="sectitle0030">Conclusions</title> <p id="abspara0025">IAC + R was useful for patients with MIBC. Successful completion and optimal patient selection were important for this treatment strategy.</p> </sec> </abstract>